Medicine machine man, find a new outlet?

Recently, Tofflon has released a number of recruitment information to the outside world.
The positions recruited involve senior verification engineers (biopharmaceutical equipment), and the qualifications include "more than 5 years of experience in equipment verification in the biopharmaceutical equipment industry.
System and clean engineering project verification related verification work experience is preferred
.
” At the same time, it is required to meet the requirements of "mastering the knowledge of computer system verification, understanding the verification requirements of China, the European Union and the United States cGMP, and being familiar with the production equipment verification of sterile preparations .

"
Medicine machine man, find a new outlet? (Source: Pharmaceutical Network) The biopharmaceutical industry is a strategic emerging industry that has been vigorously developed in China.
Against the background of an aging population, escalating consumption, as well as a series of favorable national policy support, talent influx, and capital increase, China’s The biopharmaceutical industry has broad market prospects
.
The industry predicts that by 2025, the market size of China's biopharmaceutical industry alone will exceed 800 billion yuan
.
Biopharmaceutical equipment belongs to the upstream of the biopharmaceutical industry, including a series of equipment such as bioreactors, chromatography columns, filters, and light inspection machines
.
With the rapid development of the biopharmaceutical industry, upstream biopharmaceutical equipment will also usher in a new round of development opportunities, and the high-end pharmaceutical equipment market will grow
.
Guosen Securities once mentioned in a report that the high-end market share of China's pharmaceutical equipment has increased from 24% in 2015 to 28% in 2019
.
With the rapid development of the biopharmaceutical industry, it is expected that the market share of high-end pharmaceutical equipment will increase to 32% by 2024
.
At the same time, the localization rate of China's biopharmaceutical equipment, especially core equipment, is still relatively low.
As domestic pharmaceutical machinery companies continue to increase investment in innovative research and development, and actively deploy the field of biopharmaceutical equipment, the pace of import substitution will also accelerate in the future
.
According to data, by 2025, the total market size of domestic biopharmaceutical equipment consumables will exceed 30 billion, and the average localization rate will increase from the current 20% to 30%-40%.
The market share owned by domestic enterprises may exceed 30 billion.
10 billion
.
In general, the situation of the domestic biopharmaceutical equipment industry is very good
.
In recent years, local pharmaceutical machine giants represented by Chutian Technology and Tofflon have all deployed in this field and actively deployed international business
.
With the needs of business development, these companies continue to expand their demand for relevant professional and high-level talents
.
In the pharmaceutical industry, the verification of pharmaceutical equipment has clear requirements, and only through equipment verification can the production of medicines be more stable
.
According to industry insiders, all products of pharmaceutical equipment manufacturers must be verified before production, including from equipment verification to public system verification, and then to quality risk assessment
.
Therefore, the verification engineer is a very important position
.
However, verification is a huge system, and equipment verification can be extended to engineering management, quality management, etc.
, which also puts forward higher requirements for verification engineers
.
"Generally speaking, equipment verification engineers need to master the terms, regulations and corresponding guidelines of GMP, and also be familiar with the contents of public systems, equipment, processes, computerized system verification, etc.

" According to the job description of the pharmaceutical equipment engineer, it mainly includes 6 aspects such as writing phased project verification documents, investigating, processing, evaluating and analyzing the general abnormal conditions during the project equipment verification process, participating in customer on-site acceptance activities and troubleshooting found problems
.
The job requirements not only require a wealth of work experience, but also need to be familiar with the verification requirements of China, the European Union and the United States
.
In general, the requirements are relatively strict
.
The analysis believes that this is mainly related to Tofflon's business needs.
The company mentioned in the recruitment introduction that the company is conducting domestic and overseas job recruitment according to its international business development needs to meet employment needs in a timely manner
.
It is understood that, especially for overseas pharmaceutical companies, equipment verification is particularly valued
.
Tofflon has clearly stated that it will continue to deepen the international market, strengthen the promotion of new products, and steadily increase its international market share
.
Therefore, it is speculated that the company's recruitment of biopharmaceutical equipment engineers may also be an important part of promoting the realization of its export business goals.

.
Not only Tofflon, but Chutian Technology has also clearly set international business development goals: in the next 3-5 years, the company plans to maintain an annual increase of 10%-20% in export business.
It is planned that around 2025, the export business of Chutian headquarters Revenue accounts for 40%-50% of total revenue
.
The author noticed that in order to meet the needs of business development, Chutian Technology is also actively recruiting talents for positions such as international market specialists, international business development managers, and international service engineers at the end of 2021
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.